Thank you This live web event has ended. Thank you for attending. Contributors Linzhi Chen, Boehringer Ingelheim Pharmaceuticals, Inc. Dr. Linzhi Chen is a senior principal scientist at Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT. He is the nonGLP bioanalytical group leader at DMPK Development US. His group is responsible for metabolite profiling and identification for all BIPI animal and human ADME studies and LC/MS bioanalytical support of preclinical and clinical biotherapeutic development. His recent research focuses on development of highly sensitive immunocapture-LC/MS assays for quantitation of biotherapeutics and ADA analysis. Dr. Chen has more than 20 years pharmaceutical industry experiences in the area of DMPK. Hao Jiang, Bristol-Myers Squibb Co. Dr. Hao Jiang is currently a Senior Research Investigator II at Bristol-Myers Squibb Company (BMS). He completed his PhD in Clinical Pharmacology at Peking Union Medical College in Beijing and continued his postdoc training in Pharmacology and Toxicology at University of Pennsylvania. In 2007, he joined BMS at the department of Analytical and Bioanalytical Development where he has led a group to develop many sensitive and accurate LC-MS assays for drug candidates and biomarkers in biological matrices. His work has supported PK/PD evaluation in many drug development programs such as immuno-oncology, virology, cardiovascular, and neoscience. In recent several years, he has focused on LC-MS quantitation of proteins and peptides in biological matrices for accessing pharmacokinetics, biomarker, and immunogenicity in biotherapeutic development. Dr. Jiang is a pioneer in absolute quantitation of protein therapeutics and anti-drug antibodies in regulated bioanalysis using LC-MS. He has 40 research publications in the peer-reviewed journals and 37 conference presentations, and he is an active member of American Association of Pharmaceutical Scientists (AAPS).